Summary
Hepatic metastases from soft tissue sarcomas are rare and usually are associated with advanced and disseminated disease with a poor overall prognosis. Although complete hepatic resection may provide an increase in survival, most patients are unresectable. Given the lack of effective systemic therapy, RFA may have a role in the treatment of sarcoma metastases. Although experience is limited, RFA does appear to be well tolerated and initially effective. Local recurrence remains a problem, although the ability to repeat the ablative procedure is a distinct advantage. The use of RFA with hepatic resection and or systemic therapy remains to be evaluated but may potentially increase palliation and even long-term survival in these patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Wallace S, Ajani JA, Charnsangavej C, et al. Carcinoid tumors: imaging procedures and interventional radiology. World J Surg 1996; 20(2):147–156.
Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoem-bolization of progressive carcinoid liver metastasis. Radiology 1993; 189(2):541–547.
Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79(4):813–829.
Oberg K. Carcinoid tumors: current concepts in diagnosis and treatment. Oncologist 1998; 3(5):339–345.
Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340(11):858–868.
Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res 2001; 95(1):8–12.
Oberg K. Neuroendocrine gastrointestinal tumors—a condensed overview of diagnosis and treatment. Ann Oncol 1999; 10(suppl 2): S3–8.
Norheim I, Oberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987; 206(2):115–125.
McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108(6):1091–1096.
Oberg K. The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin North Am 1993; 22(4): 941–952.
Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 2001; 25(6):693–696.
Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoem-bolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71(8):2624–2630.
Dousset B, Saint-Marc O, Pitre J, et al. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996; 20(7):908–914; discussion 914–905.
Nave H, Mossinger E, Feist H, et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 2001; 129(2):170–175.
Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169(1):36–42.
Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg 1995; 19(1):76–82.
Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoem-bolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998; 175(5):408–412.
Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997; 225(4):355–364.
Hajarizadeh H, Ivancev K, Mueller CR, et al. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg 1992; 163(5):479–483.
Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17(2):600–606.
O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000; 88(4):770–776.
Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Intervent Radiol 1999; 10(4):397–403.
Clouse ME, Perry L, Stuart K, et al. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 1994; 55(suppl 3):92–97.
Marlink RG, Lokich JJ, Robins JR, et al. Hepatic arterial embolization for metastatic hormone-secreting tumors. Technique, effectiveness, and complications. Cancer 1990; 65(10):2227–2232.
Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83(11):2293–2301.
Siperstein AE, Rogers SJ, Hansen PD, et al. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery 1997; 122(6):1147–1154; discussion 1154–1155.
Lawrence W Jr, Neifeld JP. Soft tissue sarcomas. Curr Probl Surg 1989; 26(11):753–827.
Hafner GH, Rao U, Karakousis CP. Liver metastases from soft tissue sarcomas. J Surg Oncol 1995; 58(1):12–16.
Merimsky O, Terrier P, Stanca A, et al. Liver metastases from extremity soft tissue sarcoma. Am J Clin Oncol 1999; 22(1):70–72.
Jaques DP, Coit DG, Casper ES, et al. Hepatic metastases from softtissue sarcoma. Ann Surg 1995; 221(4):392–397.
Torosian MH, Friedrich C, Godbold J, et al. Soft-tissue sarcoma: initial characteristics and prognostic factors in patients with and without metastatic disease. Semin Surg Oncol 1988; 4(1):13–19.
Foster JH. Survival after liver resection for secondary tumors. Am J Surg 1978; 135(3):389–394.
de Baere T, Elias D, Dromain C, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR 2000; 175(6):1619–1625.
Wood TF, Rose DM, Chung M, et al. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; 78(8):593–600.
Rossi S, Buscarini E, Garbagnati F, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR 1998; 170(4):1015–1022.
Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR 1996; 167(3):759–768.
Solbiati L, Ierace T, Goldberg SN, et al. Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients. Radiology 1997; 202(1):195–203.
Pearson AS, Izzo F, Fleming RY, et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999; 178(6):592–599.
Rights and permissions
Copyright information
© 2004 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
Parikh, A.A., Fornage, B., Curley, S.A., Ellis, L.M. (2004). Radiofrequency Ablation of Carcinoid and Sarcoma Liver Metastases. In: Radiofrequency Ablation for Cancer. Springer, New York, NY. https://doi.org/10.1007/0-387-21598-0_7
Download citation
DOI: https://doi.org/10.1007/0-387-21598-0_7
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-95564-3
Online ISBN: 978-0-387-21598-3
eBook Packages: Springer Book Archive